



CESCA THERAPEUTICS TO PRESENT AT THE 2017 CELL & GENE MEETING ON THE MESA

RANCHO CORDOVA, CA, September 27, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dalip Sethi, Ph.D., senior director of research and development, will participate in the 2017 Cell & Gene Meeting on the Mesa, which is being held October 4-6, 2017 at the Estancia La Jolla Hotel in La Jolla, California. Dr. Sethi will present an overview of Cesca Therapeutics' autologous cell processing capabilities on Wednesday, October 4 at 11:30am in La Jolla Ballroom 2.

For more information, please visit <http://www.meetingonthemesa.com>.

About the Cell & Gene Meeting on the Mesa

The Cell & Gene Meeting on the Mesa is a three-day conference combining discussions between key opinion leaders, senior executives and top academic researchers in the field of regenerative medicine. The program also includes 60+ presentations by the field's most promising companies and poster abstracts by leading scientists from around the globe.

About Cesca Therapeutics Inc.

Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.

Forward-Looking Statement

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics' annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

Company Contact:

Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com

Investor Contact:

Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com

###